Investigational drug · Phase 3
Savolitinib
Also called: hmpl-504, AZD6094
Not approved by FDA. In 11 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Carcinoma, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
11
8 still active
All registered trials
48
Any phase or sponsor naming "Savolitinib"
First trial start
2017
Jul 25, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Savolitinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Carcinoma
- Non-small Cell Lung Cancer
- Non-Small Cell Lung Cancer
- Carcinoma, Renal Cell
- Kidney Neoplasms
- Urologic Neoplasms
- Kidney Diseases
- Neoplasms by Site
- Enzyme Inhibitors
- Protein Kinase Inhibitors
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Savolitinib" as an intervention, largest first.
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04322890 · 6,000 participants (planned) · Start Apr 16, 2020 · Primary completion Dec 24, 2026
Drug: Osimertinib; Alectinib 150 MG and 3 more · For: Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation and 2 more
Sites: Changsha, China
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsPivotal-lookingCompleted
UNICANCERAcademic, hospital or other
NCT02117167 · 999 participants · Start Apr 23, 2014 · Primary completion Dec 22, 2018
Drug: AZD2014; AZD4547 and 9 more · For: Non-small Cell Lung Cancer Metastatic
Sites: Avignon, France; Besançon, France; Bobigny, France · 37 sites in all
- Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLCPivotal-lookingActive, not recruiting
HutchmedIndustry
NCT05009836 · 412 participants (planned) · Start Sep 6, 2021 · Primary completion May 30, 2028
Drug: Savolitinib; Placebo and 1 more · For: Non-small Cell Lung Cancer
Sites: Guangzhou, China
- Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior OsimertinibPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT03778229 · 367 participants · Start Jan 9, 2019 · Primary completion Aug 23, 2024
Drug: Osimertinib; Savolitinib and 1 more · For: Carcinoma
Sites: La Jolla, California; Los Angeles, California; Sacramento, California · 90 sites in all
- AZD9291 in Combination With Ascending Doses of Novel TherapeuticsActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT02143466 · 344 participants · Start Aug 5, 2014 · Primary completion Mar 4, 2020
Drug: Part A - AZD9291 in combination with AZD6094; Part A - AZD9291 in combination with continuous selumetinib (Asian subjects) and 9 more · For: Advanced Non Small Cell Lung Cancer
Sites: Atlanta, Georgia; Boston, Massachusetts; New York, New York · 42 sites in all
- Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05261399 · 341 participants · Start Aug 3, 2022 · Primary completion Jul 6, 2026
Drug: Savolitinib; Osimertinib and 3 more · For: Carcinoma; Non-Small-Cell Lung
Sites: Orlando, Florida; Honolulu, Hawaii; New Brunswick, New Jersey · 214 sites in all
- Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT03944772 · 247 participants · Start Jun 25, 2019 · Primary completion May 6, 2025
Drug: Osimertinib; Savolitinib and 11 more · For: Non-Small Cell Lung Cancer
Sites: Duarte, California; Los Angeles, California; Sacramento, California · 47 sites in all
- Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET AmplificationPivotal-lookingCompleted
Hutchison Medipharma LimitedIndustry
NCT05015608 · 216 participants · Start Nov 22, 2021 · Primary completion Aug 22, 2025
Drug: Savolitinib + Osimertinib; Pemetrexed + Cisplatin /Carboplatin · For: Non-small Cell Lung Cancer
Sites: Shanghai, China
- Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) PatientsPivotal-lookingCompleted
Hutchison Medipharma LimitedIndustry
NCT04923945 · 203 participants · Start Aug 19, 2021 · Primary completion Nov 30, 2024
Drug: Savolitinib · For: Non-small Cell Lung Cancer Metastatic
Sites: Shanghai, China
- Prostate Cancer Biomarker Enrichment and Treatment SelectionActive, not recruiting
Canadian Cancer Trials GroupResearch network
NCT03385655 · 200 participants · Start Aug 1, 2018 · Primary completion Oct 7, 2024
Drug: Adavosertib; Savolitinib and 5 more · For: Prostate Cancer
Sites: Edmonton, Canada; Vancouver, Canada; Halifax, Canada · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Structural analysis and crystallography-guided pharmacophore elucidation of capmatinib analogues as selective c-MET targeting anticancer agents.
Valipour M · Eur J Med Chem 2027
- A tri-scale in silico framework integrating pharmacovigilance and mechanistic modeling suggests tepotinib-associated acute kidney injury risk.
Zheng R, Chen J, Han J, et al. · Ren Fail 2026
- Osimertinib-Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy.
Lu S, Girard N, Yang JC, et al. · N Engl J Med 2026
- Repaglinide metabolism by human hepatocytes reveals CYP2C8 dominance and misassignment of CYP3A4 by liver subcellular fractions and recombinant enzymes.
Bapiro TE · Drug Metab Dispos 2026
- Evaluating the Impact of CYP1A2 Inhibition on the Pharmacokinetics of Savolitinib: A Phase 1 Open-Label Study.
Miah K, Reddy J, Sharma P, et al. · Pharmacol Res Perspect 2026
- Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study.
Ahn MJ, de Marinis F, Cho BC, et al. · Clin Cancer Res 2026
Also in development for Carcinoma
- STAR0602InvikafuspPhase 22 trials
Marengo Therapeutics, Inc. · Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer, Advanced Solid Tumors
- KVA12123Phase 21 trial
Kineta Inc. · Cancer, Solid Tumor, Melanoma
- NRC-2694-APhase 21 trial
NATCO Pharma Ltd. · Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
- ST-067Phase 21 trial
Simcha IL-18, Inc. · Cancer, Solid Tumor, Melanoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.